How is the GT20029 different to pyrilutamide as an androgenic antagonist
    Research/Science 1/14/2025

    At a glance
    In this educational post the tone is 😐 neutral.
    GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.
    View this post in the Community →

    Similar Community Posts Join

    5 / 1000+ results

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  134 upvotes 8 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

    Related Research

    6 / 1000+ results